$CELC

Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside

Analyst estimates for Celcuity Inc. show the average 12-month price target was cut from $163.55 to $160.64, with a range of $140 to $178 per share, according to 11 analysts. Based on the Aug. 13 closing price, the target suggests about 85% upside. The consensus rating remains “Buy” with 12 Buys, 0 Holds, and 0 Sells.

Original reporting
Published Aug 14, 2026, 12:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 10:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside — source image
Decision brief

The 30-second read

$CELCNeutralLow
01

Why it matters

This is a sentiment/expectations update rather than a new fundamental disclosure. The implied upside remains high, but the average target is slightly lower.

02

Market read

Traders may treat this as a mild sentiment headwind, but without new operating or clinical information it is unlikely to drive a major repricing by itself.

03

What to watch

The article does not state which analysts changed targets, whether any thesis was revised, or whether the Aug. 13 close moved materially; those details could matter more than the average target level.

Relevance 4/10Novelty 4/10Timing: today’s analyst price-target update (published 2026-08-14)

Background

The article summarizes FactSet-derived analyst consensus for Celcuity’s 12-month price target and rating distribution.

Company-level read

Ticker impact

$CELCNeutralMedium confidence
Context

Celcuity’s consensus 12-month price target was cut from $163.55 to $160.64, with analyst forecasts spanning $140 to $178.

Expected impact

Likely limited near-term impact unless the broader analyst note set includes thesis changes; this reads as a target adjustment rather than a new fundamental catalyst.

Evidence & confidence

The only disclosed change is the average price target level and the implied upside, with no new company-specific operating, regulatory, or clinical datapoint.

Market effects

Minimal, since the piece provides no sector-wide regulatory, trial, or reimbursement update.

None indicated.

None indicated.

Counterpoint

A target cut can reflect reduced confidence in near-term catalysts even if the rating stays Buy; traders may fade the implied upside if the underlying thesis deteriorated off-screen.

Key entities

  • Celcuity Inc.

    Subject of the article, with an average 12-month price target cut to $160.64 and consensus rating still Buy.

Related articles

$CELCMed

Celcuity Q2 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported Q2 earnings call highlights for its gedatolisib programs. In REVTORPYK, adverse-event discontinuations were 5.2% (mutant cohort) for the triplet and 3.8% for the doublet, versus 19% for alpelisib. The company is expanding VIKTORIA-2 and advancing a prostate Phase Ib/II trial with darolutamide. Q2 net loss was $78.9M ($1.44/share). Cash totaled $754M.

$CELCMedAI 8/10

Celcuity Inc. (CELC): Results of Operations and Financial Condition

Celcuity Inc. (CELC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 celc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update • REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or meta

$CELCMed

Newly FDA-approved Revtorpyk wins NCCN listing

Celcuity (NASDAQ: CELC) said its Revtorpyk (gedatolisib) plus fulvestrant, with or without palbociclib, was added to NCCN Guidelines as a preferred Category 1 option for HR+, HER2- advanced or metastatic breast cancer after endocrine therapy progression. FDA approved Revtorpyk on July 14, 2026 for HR+/HER2- disease without detected PIK3CA mutation.

$CELCMedAI 9/10

REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Breast Cancer, US

Celcuity’s REVTORPYK (gedatolisib) was approved by the US FDA in July 2026 for HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA wild-type, in combination with fulvestrant, with or without palbociclib, after progression on endocrine therapy. VIKTORIA-1 (n=392) showed arm A median PFS 9.3 vs 2.0 months for fulvestrant alone, ORR 32% vs 1%. Commercial launch planned for late Q3 2026.

$CELCMedAI 8/10

Celcuity faces securities fraud probe

Pomerantz LLP says it is investigating Celcuity Inc. for possible securities fraud after Celcuity announced a delayed commercial launch for its FDA-approved breast cancer drug Revtorpyk. The launch was pushed to late Q3 2026, later than analysts expected, and Celcuity shares fell 17.6% on July 15, 2026. The probe concerns whether the delay involved unlawful practices.

$CELCMedAI 8/10

Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer

Celcuity (Nasdaq: CELC) said the FDA approved REVTORPYK (gedatolisib) with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation after at least one endocrine therapy line. The VIKTORIA-1 data showed a progression-free survival benefit, with higher stomatitis, rash and metabolic side effects. The stock was reported down 17.4%.